BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: A systematic review and meta-analysis

Brunoni, Andr É R.; Baeken, Chris; Machado‐Vieira, Rodrigo; Gattaz, Wagner F.; Vanderhasselt, Marie‐Anne

doi:10.3109/15622975.2014.958101

Cited by 42 publications

(26 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At least five previously published meta-analyses have shown that peripheral BDNF levels were consistently lower in MDD patients when compared to healthy controls, while antidepressant therapy and non-pharmacological treatments such as electroconvulsive therapy (ECT) increased low circulating BDNF levels (Bocchio-Chiavetto et al, 2010;Brunoni et al, 2014Brunoni et al, , 2008Sen et al, 2008). Conversely, peripheral BDNF levels did not appear to change following treatment with non-invasive brain stimulation interventions (Brunoni et al, 2015). Nevertheless, a recent extensive meta-analysis indicated that the difference in serum BDNF levels between individuals with MDD and healthy controls is slimmer than once thought (Molendijk et al, 2014).…”

Section: Introductionmentioning

confidence: 90%

Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis

Carvalho

Köhler

McIntyre

et al. 2015

Psychoneuroendocrinology

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 90%

Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis

Carvalho

Köhler

McIntyre

et al. 2015

Psychoneuroendocrinology

Self Cite

View full text Add to dashboard Cite

“…9,23 Moreover, several studies showed that BDNF plasma levels do not increase after tDCS treatment in depression. 32,[49][50][51] Regarding the SLC6A4 serotonin transporter polymorphism studied herein, the short allele (s) is related to lower availability and activity of the serotonin transporter compared to its long form. In fact, subjects with the s allele display worse clinical response to SSRIs, probably because the efficacy of SSRIs decreases when the serotonin transporter is not functioning optimally.…”

Section: Discussionmentioning

confidence: 99%

Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial

Brunoni

Carracedo

Amigo

et al. 2020

Braz. J. Psychiatry

View full text Add to dashboard Cite

Objective: We investigated whether single nucleotide polymorphisms (SNPs) associated with neuroplasticity and activity of monoamine neurotransmitters, such as the brain-derived neurotrophic factor (BDNF, rs6265), the serotonin transporter (SLC6A4, rs25531), the tryptophan hydroxylase 1 (TPH1, rs1800532), the 5-hydroxytryptamine receptor 2A (HTR2A, rs6311, rs6313, rs7997012), and the catechol-O-methyltransferase (COMT, rs4680) genes, are associated with efficacy of transcranial direct current stimulation (tDCS) in major depression. Methods: Data from the Escitalopram vs. Electrical Current Therapy for Treating Depression Clinical Study (ELECT-TDCS) were used. Participants were antidepressant-free at baseline and presented with an acute, moderate-to-severe unipolar depressive episode. They were randomized to receive escitalopram/tDCS-sham (n=75), tDCS/placebo-pill (n=75), or placebo-pill/sham-tDCS (n=45). General linear models assessed the interaction between treatment group and allele-wise carriers. Additional analyses were performed for each group and each genotype separately. Results: Pairwise group comparisons (tDCS vs. placebo, tDCS vs. escitalopram, and escitalopram vs. placebo) did not identify alleles associated with depression improvement. In addition, exploratory analyses also did not identify any SNP unequivocally associated with improvement of depression in any treatment group. Conclusion: Larger, combined datasets are necessary to identify candidate genes for tDCS response.

show abstract

“…Many studies have addressed the clinical importance of BDNF in psychiatric diseases, and significant changes of the plasma BDNF levels for each condition have been demonstrated; 35 36 37 38 furthermore, some of the researchers also reported the recovery of lowered plasma BDNF levels, especially for depressive disorders, after proper treatment. 39 40 41 For somatization, however, investigation results regarding the implications of BDNF are extremely rare.…”

Section: Discussionmentioning

confidence: 99%

Decreased Plasma BDNF Levels of Patients with Somatization Disorder

Kang

Park

Kim

et al. 2016

Psychiatry Investig

View full text Add to dashboard Cite

ObjectiveBrain-derived neurotrophic factor (BDNF), one of the most abundant and important neurotrophins, is known to be involved in the development, survival, maintenance, and plasticity of neurons in the nervous system. Some studies have suggested that BDNF may play a role in the pathophysiology of several psychiatric illnesses such as depression and schizophrenia. Similarly, it is likely that the alteration of BDNF may be associated with the neuro-modulation that contributes to the development of somatization disorder.MethodsThe purpose of this study was to determine whether there is an abnormality of plasma BDNF levels in patients with somatization disorder, and to analyze the nature of the alteration after pharmacotherapy using an enzyme-linked immunosorbent assay (ELISA).ResultsThe plasma BDNF levels of the patients with a somatization disorder were significantly lower compared with those of the control volunteers (83.61±89.97 pg/mL vs. 771.36±562.14 pg/mL); moreover, the plasma BDNF levels of those patients who received an antidepressant were significantly increased after the treatment (118.13±91.45 pg/mL vs. 72.92±88.21 pg/mL).ConclusionThese results suggest that BDNF may play a role in the pathophysiology of somatization disorder.

show abstract

BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: A systematic review and meta-analysis

Cited by 42 publications

References 39 publications

Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis

Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis

Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial

Decreased Plasma BDNF Levels of Patients with Somatization Disorder

Contact Info

Product

Resources

About